Global Parkinson's Disease (PD) Drugs Sales Market Report 2021

Parkinson's disease (PD) is a progressive neurodegenerative disorder characterized by damage to the dopaminergic neurons located in various parts of the brain, including the substantia nigra.
The emergence of gene therapy to reverse the progression of PD is one of the key trends that will gain traction in the market for parkinsons drugs throughout the estimated period.

Market Analysis and Insights: Global Parkinson's Disease (PD) Drugs Market
The global Parkinson's Disease (PD) Drugs market was valued at US$ XX in 2020 and will reach US$ XX million by the end of 2027, growing at a CAGR of XX% during 2022-2027.

Global Parkinson's Disease (PD) Drugs Scope and Market Size
The global Parkinson's Disease (PD) Drugs market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Parkinson's Disease (PD) Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by region (country), by Type and by Application for the period 2016-2027.

Segment by Type
Dopamine Agonist
Monoamine Oxidase Inhibitors
Acetylcholinesterase Inhibitors
Glutamate Inhibitors

Segment by Application
Hospital
Family

The Parkinson's Disease (PD) Drugs market is analysed and market size information is provided by regions (countries). Segment by Application, the Parkinson's Disease (PD) Drugs market is segmented into North America, Europe, China, Japan, Southeast Asia, India and Other Regions.

By Company
Boehringer Ingelheim
GlaxoSmithKline
Novartis
Teva Pharmaceutical Industries
AbbVie
Abital Pharma
Addex Therapeutics
Biogen
Eisai
Eli Lilly
F. Hoffmann-La Roche
H. Lundbeck
Impax Laboratories
Kyowa Hakko Kirin
Otsuka Pharmaceutical
Pfizer